New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 16, 2014
08:32 EDTOMEDOncoMed initiates Phase 2 ALPINE trial of tarextumab
OncoMed Pharmaceuticals announced that patient dosing has begun in the randomized, placebo-controlled Phase 2 portion of the company's "ALPINE", or Antibody therapy in first-Line Pancreatic cancer Investigating anti-Notch Efficacy and safety, clinical trial of its anti-Notch 2/3 cancer stem cell antibody, tarextumab, being studied for the treatment of pancreatic cancer. Tarextumab is being tested in combination with Abraxane plus gemcitabine in patients with previously untreated stage IV pancreatic cancer. The ALPINE trial is being conducted at up to 30 sites in the U.S. and is expected to enroll approximately 124 patients. The Phase 2 clinical trial will compare the progression-free survival, or PFS, of 15 mg/kg tarextumab administered every two weeks versus placebo in combination with Abraxane plus gemcitabine in all patients. Additionally, PFS will be assessed using a predictive biomarker for high tumor Notch3 expression. Secondary and exploratory endpoints, including overall survival and overall response rate, pharmacokinetics, safety and other biomarkers, will also be evaluated.
News For OMED From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
09:36 EDTOMEDOncoMed management to meet with Leerink
Meeting to be held in New York on October 27 hosted by Leerink.
October 14, 2014
09:39 EDTOMEDOncoMed management to meet with Leerink
Subscribe for More Information
07:15 EDTOMEDBiotech Industry Organization to hold a summit
Subscribe for More Information
October 7, 2014
10:02 EDTOMEDOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:33 EDTOMEDOncoMed initiated with an Outperform at JMP Securities
Target $28.
07:16 EDTOMEDBiotech Industry Organization to hold a forum
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use